Loading
Latest filing published 18 May 2018 for Ocugen, Inc., €3,639.
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Filings by Adam Gridley span 2 companies, the busiest being Bioform Medical Inc and Ocugen, Inc. We count 13 filings; the first trade dates from 24 August 2009 and the latest from 16 May 2018.
The open-market side counts 2 purchases for €13k alongside 5 sales for €67k. Taken together, the sales exceed the purchases by €54k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 5 option exercises. So far in 2018, the count stands at 1 purchase and no sales.
The latest filing, published on 18 May 2018, reports an open-market purchase of €3,639 in Ocugen, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
13 of 13 declarations